A Preliminary Report on the Role of Liv.52 – An Indigenous Drug in Serum B Hepatitis Cases

Patney, N.L., M.D., M.A.M.S. (Med.), M.R.C.P. (Lond.), M.R.C.P. (Glas.), D.T.M.& H. (Edin.), D.T.C.D. (Wales) and Ashok Kumar, M.Sc. Postgraduate Department of Medicine, S.N. Medical College, Agra, India.

Table 1A: Mean results of haematological examination in the Control group before and after receiving regimen I without Liv.52
Timings			Hb g%		TLC cells/mm	DLC			ESR mm fall 1st hr.
P										L										E
On admission			11.0 ± 2.14		9800	79	20	1	48
After 1st month			11.0 ± 2.00		9200	78	21	1	35
2nd month			11.2 ± 1.96		10000	82	17	–	32
3rd month			11.2 ± 2.96		11000	80	20	–	30
4th month			11.4 ± 2.30		11500	75	25	–	27
6th month			11.5 ± 1.93		12000	76	24	–	25

Table 1B: Mean results of haematological examination in the Test group before and after receiving regimen II with Liv.52
Timings			Hb g%		TLC cells/mm	DLC			ESR mm fall 1st hr.
P										L										E
On admission			11.5 ± 1.82		8500	80	19	1	40
After 1st month			11.7 ± 1.63		8300	75	25	–	35
2nd month			12.0 ± 2.06		8350	70	30	–	32
3rd month			12.3 ± 2.00		8400	65	35	–	27
4th month			12.5 ± 1.84		8300	70	30	–	27
6th month			12.8 ±1.68		8300	72	38	–	16

Table IIA: Mean results of urine analysis in the Control group before and after receiving regimen I without Liv.52
Timings	Albumin	Bile salts	Bile pigments	Urobilinogen
On admission	Traces	++	++	1/30
After 1st month	Traces	+=	++	1/30
2nd month	Traces	+	++	1/20
3rd month	Nil	+	+	1/20
4th month	Nil	Nil	+	1/10
6th month	Nil	Nil	Nil	1/10

Table IIB: Mean results of urine analysis in the Test group before and after receiving regimen II with Liv.52
Timings	Albumin	Bile salts	Bile pigments	Urobilinogen
On admission	++	++	++	1/40
After 1st month	Traces	+	+	1/20
2nd month	Nil	Nil	Nil	1/10
3rd month	Nil	Nil	Nil	Nil
4th month	Nil	Nil	Nil	Nil
6th month	Nil	Nil	Nil	Nil

Liver Function Tests: On surveying the mean results of liver function tests, a marked improvement was observed in the Test group on Liv.52 as compared to the Control group. There was a rapid fall in the serum bilirubin level and a rise in the levels of total serum proteins and serum albumin. Besides this, there was an early fall in the levels of serum globulin, zinc sulphate turbidity and serum alkaline phosphatase after Liv.52 therapy (Table III B). This clearly indicates that patients of the Test group showed a good response to Liv.52 therapy.

Table IIIA: Mean results of liver function tests in the Control group before and after regimen I without Liv.52
Timings	Serum bilirubin mg%	Total serum protein g%	Albumin g%	Globulin g%	Van den Bergh reaction	T.T. units	T.F. units	Z.S.T. Units	Serum alkaline phosphatase K.A. Units
On admission	7.1 ± 2.06	6.8 ± 0.58	3.0 ± 0.53	3.8 ± 0.62	DI+	10	+2	16	46 ± 12
After 1st month	5.2 ±1.98	6.8 ± 0.93	3.2 ± 0.73	3.6 ± 0.59	DI+	6	+2	16	40 ± 16
2nd month	3.8 ± 1.62	6.9 ± 1.62	3.2 ±0.37	3.7 ± 0.69	DI+	6	+1	12	35 ± 10
3rd month	2.7 ± 1.90	6.9 ±1.03	3.3 ± 0.46	3.6 ± 0.38	DI+	4	+1	10	31 ± 13
4th month	1.8 ± 1.34	7.0 ± 0.86	3.4 ± 0.72	3.6 ± 0.63	DD+	3	Neg.	10	27 ± 9
6th month	1.6 ± 1.00	7.1 ± 0.63	3.5 ± 0.45	3.6 ± 0.81	Neg.	3	Neg.	8	18 ± 9

Refference: http://www.himalayahealthcare.com/pdf_files/liv236.pdf